“We expect the company’s topline to grow at a seven-year CAGR of 26.3% from $159.6M in 2018 to $819.1M in 2025. We expect mid- to long-term overall gross margins to fluctuate between 60-70%, driven by lumpiness of the high margin revenues from grants and collaboration. We are projecting operating expenses to grow at a seven-year CAGR of 5.0% from 2018 to 2025. We expect the company to generate positive net profit beginning in 2020. Based on these assumptions, we arrive at a valuation of $11.00 per share for AMRS stock.”
According to TipRanks.com, Dayal has 0 stars on 0-5 star ranking scale with an average return of -13.9% and a 27.9% success rate. Dayal covers the Industrial Goods sector, focusing on stocks such as Ballard Power Systems, Capstone Turbine Corp, and Orion Energy Systems.
Amyris has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
Based on Amyris’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $68.32 million. In comparison, last year the company had a GAAP net loss of $33.86 million.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amyris, Inc. is an industrial biotechnology company, which engages in the provision of bioscience solutions. It focuses on the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants. The company was founded by Jack D.